PMID: 15220700Jun 29, 2004Paper

Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine

Journal of Acquired Immune Deficiency Syndromes : JAIDS
J Tyler LonerganESS40010 (TARHEEL) Study Team

Abstract

Stavudine (d4T) has been observed in clinical trials and cohort studies to be more often implicated in cases of hyperlactatemia than other nucleoside reverse transcriptase inhibitors, possibly because of its relatively greater propensity to induce mitochondrial toxicity. The ESS40010 study was a 48-week, open-label, switch study that assessed changes in serum lactate levels and signs/symptoms of hyperlactatemia after substitution of abacavir (n = 86) or zidovudine (n = 32) for d4T in 118 virologically suppressed HIV-infected patients (HIV-1 RNA <400 copies/mL) who had developed serum lactate concentrations > or =2.2 mmol/L (n = 16) or had remained normolactatemic (n = 102) after receiving > or =6 months of d4T-based treatment. Median serum lactate decreased significantly below baseline at week 24 (-0.15 mmol/L, P = 0.0002) and week 48 (-0.15 mmol/L, P = 0.0015). In 10 hyperlactatemic patients in whom d4T was discontinued, serum HIV-1 RNA levels rebounded over the ensuing 31 days, but virologic suppression (HIV-1 RNA <400 copies/mL) was regained when treatment using abacavir or zidovudine was subsequently instituted. In the group with elevated lactate at baseline, symptoms of hyperlactatemia improved in 8% to 23% of patients, di...Continue Reading

References

Jul 29, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J T LonerganW C Mathews
Jul 29, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K Brinkman
Nov 3, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K BoubakerA Telenti
Apr 20, 2002·Current Opinion in Infectious Diseases·Mina John, Simon Mallal
Jul 4, 2002·JAMA : the Journal of the American Medical Association·Andrew CarrUNKNOWN Mitochondrial Toxicity (MITOX) Study Group
Nov 26, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Marianne HarrisJulio S G Montaner
Feb 27, 2003·Archives of Medical Research·Patricia Cornejo-JuárezPatricia Volkow-Fernández
Dec 31, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Grace A McComseyUNKNOWN Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Posit

❮ Previous
Next ❯

Citations

Jun 21, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M G Bolhaar, A S Karstaedt
Jun 21, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Judith S Currier
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Johan van GriensvenTony Reid
Oct 21, 2006·AIDS Patient Care and STDs·Andrew R LaiLynn E Taylor
Aug 22, 2013·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Asa M MargolisAndrew Stolbach
May 9, 2008·Expert Opinion on Drug Safety·Alain MakinsonEric Delaporte
Aug 17, 2005·Infectious Disease Clinics of North America·Ethan G Leonard, Grace A McComsey
Jun 1, 2012·African Journal of AIDS Research : AJAR·Viloshini Krishna Manickum, Fatima Suleman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aphasia

Aphasia affects the ability to process language, including formulation and comprehension of language and speech, as well as the ability to read or write. Here is the latest research on aphasia.